Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma
Jianjun Gao, Neema Navai, Omar Alhalabi, Arlene O. Siefker‐Radtke, Matthew T. Campbell, Rebecca S. Tidwell, Charles C. Guo, Ashish M. Kamat, Surena F. Matin, John C. Araujo, Amishi Y. Shah, Pavlos Msaouel, Paul G. Corn, Jianbo Wang, John Papadopoulos, Shalini S. Yadav, Jorge Blando, Fei Duan, Sreyashi Basu, Wenbin Liu, Yu Shen, Yuwei Zhang, Marc Macaluso, Ying Wang, Jianfeng Chen, Jianhua Zhang, P. Andrew Futreal, Colin P. Dinney, James P. Allison, Sangeeta Goswami, Padmanee Sharma
Topics & Concepts
DurvalumabMedicineTremelimumabOncologyInternal medicineNeoadjuvant therapyImmune checkpointBladder cancerCystectomyAtezolizumabCTLA-4Clinical endpointCisplatinCancerNivolumabImmunotherapyClinical trialImmune systemChemotherapyIpilimumabImmunologyT cellBreast cancerBladder and Urothelial Cancer TreatmentsUrinary and Genital Oncology StudiesCancer Immunotherapy and Biomarkers